Sernova (PSH0) Stock Price & Analysis
PSH0 Stock Chart & Stats
- Day’s Range
- EUR 0.06 - EUR 0.07
- 52-Week Range
- EUR 0.05 - EUR 0.20
- Previous Close
- EUR 0.07
- Volume
- 4,285
- Average Volume (3M)
- 23.78K
- Market Cap
- EUR 25.41M
- Enterprise Value
- EUR 56.09M
- Total Cash (Recent Filing)
- EUR 63.33K
- Total Debt (Recent Filing)
- EUR 2.58M
- Price to Earnings (P/E)
- ―
- Beta
- 0.38
- Next Earnings
- Mar 12, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Reusable Cell-Therapy Platform
The Cell Pouch System offers a potentially reusable implant platform across chronic-disease applications, including insulin-dependent diabetes. If clinical development succeeds, a scalable platform could support multiple programs and create durable strategic value beyond a single therapy.
Improving Loss Trend
The substantial reduction in net losses indicates a lower spending profile or meaningful cost control relative to prior periods. Although profitability remains distant, continued improvement could extend development runway and reduce the pace at which external capital is required.
Lower Cash-Burn Run Rate
Operating cash outflows have declined materially from 2023 and 2024 levels, suggesting improved spending discipline or a narrower development footprint. A lower burn rate can preserve resources for priority clinical work and make future financing needs more manageable.
Bears Say
No Commercial Revenue
With no reported revenue base, Sernova has not yet demonstrated commercial traction or internally funded operations. Its financial outlook remains dependent on clinical progress, regulatory approval, and eventual commercialization of its therapies or platform.
Negative Shareholders’ Equity
Negative shareholders’ equity signals accumulated financial pressure and leaves the company with limited balance-sheet resilience. This weak capital position can constrain strategic flexibility and increase dependence on future financing or other forms of external support.
Persistent External-Funding Dependence
Persistently negative operating and free cash flow show that development activities are not funded by operations. Sernova therefore remains reliant on equity financing, grants, or strategic arrangements, creating ongoing funding execution and potential dilution pressure.
Sernova News
PSH0 FAQ
What was Sernova’s price range in the past 12 months?
What is Sernova’s market cap?
When is Sernova’s upcoming earnings report date?
How were Sernova’s earnings last quarter?
Is Sernova overvalued?
Does Sernova pay dividends?
What is Sernova’s EPS estimate?
How many shares outstanding does Sernova have?
What happened to Sernova’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Sernova?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Sernova
Sernova Corp. is a Canadian clinical-stage enterprise specializing in the development and commercialization of groundbreaking regenerative medicine therapies. Its core endeavors revolve around its proprietary Cell Pouch system and associated technologies, which encompass specialized therapeutic cells and mechanisms for localized cellular immune protection. The Cell Pouch itself is an innovative medical device engineered to establish a highly vascularized tissue environment, crucial for the successful transplantation and engraftment of therapeutic cells. Once integrated, these cells are designed to secrete vital proteins or hormones, providing sustained treatment for a range of severe chronic conditions, including diabetes, hemophilia, and thyroid dysfunction. To bolster its research and development, Sernova maintains a collaborative partnership with AgeX Therapeutics, Inc. focused on generating immune-protected therapeutic cells, and an ongoing research agreement with the University of Miami to further refine its Cell Pouch cell therapy platform. Established in 1998, Sernova Corp. maintains its corporate headquarters in London, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jonathan N. Rigby
- Employees
- 8
- Website
- www.sernova.com
- Address
- RPO Central Parkway, Mississauga, ON, L5A 4H2, CA
Sernova (PSH0) Earnings & Revenues
PSH0 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 4 | 14 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 0 | 0 | 12 |
